SRPT · Sarepta Therapeutics, Inc.
$18.10
-0.32 (-1.74%)
At close · Aug 14
Market Cap
$1.91B
Shares
105.63M
Sarepta Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Sarepta Therapeutics, Inc. (SRPT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲21.6%
$230.27M
−$257.74M
'22 Q3
22-09-30
▲28.3%
$258.43M
−$109.24M
'22 Q4
23-01-09
▲20.2%
$253.50M
−$516.75M
'23 Q1
23-03-31
▲11.9%
$261.24M
−$23.94M
'23 Q2
23-06-30
▲44.1%
$331.82M
−$40.94M
'23 Q3
23-09-30
▲53.5%
$396.78M
$45.66M
'23 Q4
24-01-08
▲63.1%
$413.46M
$36.12M
'24 Q1
24-03-31
▲38.9%
$362.93M
$6.46M
'24 Q2
24-06-30
▲40.8%
$467.17M
$33.61M
'24 Q3
24-09-30
▲65.9%
$658.41M
$159.05M
'24 Q4
25-02-26
▲80.2%
$744.86M
−$447.51M
'25 Q1
25-03-31
▲68.4%
$611.09M
$196.89M
'25 Q2
25-07-16
▼14.5%
$399.36M
−$50.57M
'25 Q3
25-11-03
▼32.7%
$442.93M
−$412.23M
'25 Q4
26-02-25
▼1.9%
$730.80M
$330.96M
'26 Q1
26-05-06
LATEST
▼34.3%
$401.25M
−$4.89M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Sarepta Therapeutics Second Quarter 2026 Earnings Call
Positive tone
FSHD and DM1 readouts
siRNA pipeline
Elevidys regulatory submissions
Revenue
$401.25M
▼ 34.3% YoY Diluted EPS
$-0.05
▼ 102.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Sarepta Therapeutics, Inc. Q1 FY2026 Earnings Call
Positive tone
siRNA pipeline (FSHD and DM1)
Alevitus commercial stabilization and growth
Alevitus clinical evidence and disease modification
Revenue
$730.80M
▼ 1.9% YoY Diluted EPS
$2.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Sarepta Therapeutics, Inc. Q4 FY2025 Earnings Call
Positive tone
ELEVIDYS Commercial Initiatives & Guidance
Pipeline (siRNA Programs)
PMO Therapies (AMONDYS, VYONDYS, EXONDYS)
Revenue
$442.93M
▼ 32.7% YoY Diluted EPS
$-3.93
▼ 362% YoY Gross margin
-6.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
2026 JP Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-03
Sarepta Therapeutics, Inc. Q3 FY2025 Earnings Call
Positive tone
ESSENCE confirmatory trial results
COVID impact on trial data
Accelerated to traditional approval transition
Revenue
$399.36M
▼ 14.5% YoY Diluted EPS
$-0.50
▼ 247.1% YoY Gross margin
54.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-16
Sarepta Therapeutics, Inc. Q2 FY2025 Earnings Call
Balanced tone
ELEVIDYS label and safety update
Portfolio refocus and pipeline
ELEVIDYS revenue stress test
Revenue
$611.09M
▲ 68.4% YoY Diluted EPS
$1.89
▲ 2600% YoY Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Sarepta Therapeutics, Inc. Q1 FY2025 Earnings Call
Cautious tone
ELEVIDYS launch and guidance revision
Patient safety event and liver failure
Site capacity and top-site imbalance
Revenue
$744.86M
▲ 80.2% YoY Diluted EPS
$-4.60
▼ 1343.2% YoY Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Sarepta Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
ELEVIDYS launch and commercial performance
Financial performance and 2025 guidance
LGMD franchise pipeline
Revenue
$658.41M
▲ 65.9% YoY Diluted EPS
$1.50
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Sarepta Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
ELEVIDYS commercial performance
PMO franchise (EXONDYS, VYONDYS, AMONDYS)
Guidance and 2025 outlook
Revenue
$467.17M
▲ 40.8% YoY Diluted EPS
$0.34
Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Sarepta Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
ELEVIDYS label expansion and launch
Roche partnership and ex-US approvals
PMO franchise (Exondys, Vyondys, Amondys)
Revenue
$362.93M
▲ 38.9% YoY Diluted EPS
$0.07
Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Sarepta Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
ELEVIDYS commercial performance
Financial results and capitalization
FDA label expansion review
Revenue
$413.46M
▲ 63.1% YoY Diluted EPS
$0.37
Gross margin
74.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Sarepta Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
ELEVIDYS launch performance
Roche ex-US partnership and supply
Pipeline advancement
Revenue
$396.78M*
▲ 53.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Sarepta Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$331.82M
▲ 44.1% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Sarepta Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$261.24M
▲ 11.9% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Sarepta Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$253.50M
▲ 20.2% YoY Diluted EPS
$-5.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sarepta Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$258.43M*
▲ 28.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Sarepta Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$230.27M
▲ 21.6% YoY Diluted EPS
$-2.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Sarepta Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$233.49M
▲ 42.3% YoY Diluted EPS
$-2.65
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Sarepta Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$210.83M
▲ 43.5% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Sarepta Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$201.46M*
▲ 38.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-15
Sarepta Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$189.41M
▲ 31.6% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Sarepta Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$164.09M
▲ 19.5% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Sarepta Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$146.93M
▲ 29.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Sarepta Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$145.14M
▲ 45% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Sarepta Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$143.92M
▲ 45.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Sarepta Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$137.36M
▲ 45.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Sarepta Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$113.67M
▲ 30.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–29 of 29 earnings calls
Key facts
CIK
873303
CUSIP
803607100
13F (30d)
333 filings
300 filers
Visit website
Investor relations